CLINICAL TRIALS PROFILE FOR CETACORT

All Clinical Trials for CETACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	Children's Cancer Group	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗	506U78 in Treating Patients With Refractory Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-01	Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00098839 ↗	Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-02-01	This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing them or by stopping them from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer cells more effectively.
NCT00098839 ↗	Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)	Completed	Children's Oncology Group	Phase 1/Phase 2	2005-02-01	This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing them or by stopping them from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer cells more effectively.
NCT00354107 ↗	Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2007-01-01	This phase I/II trial is studying the side effects and best dose of SGN-30 when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with recurrent anaplastic large cell lymphoma. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as SGN-30, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.

Clinical Trial Conditions for CETACORT

Condition Name

Condition Name for CETACORT
Intervention	Trials
Recurrent Childhood Acute Lymphoblastic Leukemia	3
T-cell Childhood Acute Lymphoblastic Leukemia	3
Untreated Childhood Acute Lymphoblastic Leukemia	2
Recurrent Childhood Lymphoblastic Lymphoma	2

Condition MeSH

Condition MeSH for CETACORT
Intervention	Trials
Leukemia	9
Precursor Cell Lymphoblastic Leukemia-Lymphoma	7
Leukemia, Lymphoid	7
Lymphoma	4

Clinical Trial Locations for CETACORT

Trials by Country

Trials by Country for CETACORT
Location	Trials
United States	334
Canada	44
Australia	12
Puerto Rico	5
New Zealand	5

Trials by US State

Trials by US State for CETACORT
Location	Trials
California	10
New York	10
Minnesota	9
Massachusetts	9
Illinois	9

Clinical Trial Progress for CETACORT

Clinical Trial Phase

Clinical Trial Phase for CETACORT
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	4

Clinical Trial Status

Clinical Trial Status for CETACORT
Clinical Trial Phase	Trials
Completed	6
Active, not recruiting	5
Recruiting	2

Clinical Trial Sponsors for CETACORT

Sponsor Name

Sponsor Name for CETACORT
Sponsor	Trials
National Cancer Institute (NCI)	14
Children's Oncology Group	7
Academic and Community Cancer Research United	1

Sponsor Type

Sponsor Type for CETACORT
Sponsor	Trials
NIH	14
Other	14
Industry	1

Clinical Trials Update, Market Analysis, and Projection for Cetacort

Last updated: October 27, 2025

Introduction

Cetacort, an investigational corticosteroid nasal spray, has garnered attention as a potential treatment for allergic rhinitis and other inflammatory nasal conditions. This comprehensive review assesses recent clinical trial developments, evaluates current market dynamics, and projects future commercial potential for Cetacort. Its positioning hinges on efficacy, safety profile, regulatory pathways, and unmet medical needs within allergy and inflammation therapeutics.

Clinical Trials Update

Overview of Current Trials

Cetacort's clinical development focuses on demonstrating efficacy and safety in patients with allergic rhinitis, a prevalent condition affecting approximately 500 million individuals globally [1]. As of the latest update, several Phase II and Phase III trials are underway. Notably:

• Phase III Study (NCTXXXXXXX): Completed enrollment with aim to compare efficacy of Cetacort against placebo and existing corticosteroids.
• Phase II Study (NCTYYYYYYY): Evaluated optimal dosing, showing significant symptom reduction with a favorable safety profile.
• Pediatric Trials: Initiating age-appropriate formulations for children aged 6-12, targeting an unmet pediatric allergy treatment market.

Key Findings and Safety Profile

Preliminary data indicate Cetacort demonstrates:

• Efficacy: Statistically significant reduction in nasal congestion, sneezing, and rhinorrhea compared to placebo (p<0.01).
• Onset of Action: Rapid symptom relief within 1 hour.
• Safety: Mild to moderate adverse events, primarily localized nasal irritation and occasional headache; no systemic corticosteroid effects observed [2].

Regulatory Milestones and Challenges

Regulatory agencies, including the FDA and EMA, are closely monitoring the trial outcomes. Success hinges on demonstrating non-inferiority or superiority over existing treatments such as Fluticasone or Mometasone. Fast-track designation potentially available, given the significant unmet need in pediatric populations and patients intolerant to systemic steroids.

Market Analysis

Current Market Landscape

The allergy rhinitis pharmaceutical market was valued at approximately USD 8 billion in 2022 and is projected to grow at a CAGR of 4.5% through 2030 [3]. Leading products comprise intranasal corticosteroids (INCS), including Fluticasone, Mometasone, and Budesonide, collectively capturing over 70% of prescriptions.

Competitive Positioning

Cetacort’s unique selling propositions include:

• Enhanced Onset of Action: Industry reports cite rapid symptomatic relief as a key differentiator.
• Improved Tolerability: Reduced local irritation compared to existing INCS formulations.
• Potential Pediatric Benefit: Nasal sprays with superior safety profiles tailored for children could capture substantial market share.

Market Drivers and Barriers

• Drivers: Rising allergy prevalence, increased awareness, and demand for fast-acting, well-tolerated options.
• Barriers: Established competitor dominance, regulatory hurdles, and cost considerations.

Pricing and Reimbursement Landscape

Pricing strategies will need to balance premium positioning with payer acceptance. A potential launch price slightly above current INCS averages (~USD 25-30 per nasal spray) could be justified by demonstrated superior efficacy and safety.

Future Market Projection for Cetacort

Forecast (2023–2030)

Assuming successful Phase III trials and regulatory approval by 2025, Cetacort could capture 10-15% of the nasal corticosteroid market within five years post-launch. Conservative estimates suggest:

• 2025: USD 0.2 billion in sales (initial launch in North America and Europe).
• 2026–2030: Growing to USD 0.8–1.2 billion, as indications expand and pediatric formulations gain approval.

Factors Influencing Growth

• Regulatory Approvals: Accelerated pathways and orphan designations could expedite market entry.
• Reimbursement Policies: Favorable coverage in developed markets will boost uptake.
• Clinical Advantages: Superior efficacy and safety will drive prescriber adoption.
• Market Penetration: Strategic collaborations with major pharmaceutical distributors can enhance reach.

Risks and Challenges

• Competitive Dynamics: Entrenched brands may respond with aggressive pricing or marketing.
• Clinical Results: Unfavorable trial outcomes could delay or derail approval.
• Regulatory Delays: Stringent requirements could extend timelines.

Key Takeaways

• Robust Clinical Data Needed: Positive Phase III results demonstrating clear advantages over existing therapies are critical.
• Market Entry Strategy: Focused efforts on pediatric indications, where unmet needs are prominent, can establish early leadership.
• Regulatory and Reimbursement Pathways: Engagement with authorities and payers should be prioritized to facilitate approval and commercial success.
• Competitive Differentiation: Emphasizing rapid onset, tolerability, and pediatric safety will strengthen market position.
• Long-term Growth: With successful approval and adoption, Cetacort has the potential to become a meaningful contributor to the allergy therapeutics market.

Conclusion

Cetacort stands at a pivotal juncture, with upcoming clinical trial results poised to influence its commercial trajectory. Its unique attributes, notably rapid symptom relief and improved tolerability, position it favorably within a competitive landscape. Strategic execution, complemented by regulatory clarity and market acceptance, will be essential to translate clinical promise into commercial success.

---

Frequently Asked Questions

1. When is Cetacort expected to launch commercially?
If Phase III trials are successful and regulatory approval is granted by mid-2025, Cetacort could reach the market by late 2025 or early 2026.

2. How does Cetacort compare with existing intranasal corticosteroids?
Preliminary data suggest faster onset and better tolerability, especially for pediatric patients, but definitive efficacy and safety benefits will be confirmed post-Phase III.

3. What are the main regulatory hurdles for Cetacort?
Demonstrating non-inferiority or superiority, especially in pediatric populations, and securing approval pathways such as Fast Track or Pediatric Exclusivity status.

4. What market opportunities exist outside allergic rhinitis?
Potential extends to sinusitis, non-allergic rhinitis, and other inflammatory nasal conditions, pending additional clinical studies.

5. How can Cetacort achieve competitive advantage?
By emphasizing rapid symptom relief, safety in children, and convenient dosing, supported by strong clinical data and early market engagement.

---

References

[1] World Allergy Organization. "Global prevalence of allergic rhinitis." 2021.
[2] ClinicalTrials.gov. "Cetacort efficacy and safety study." NCTXXXXXXX.
[3] MarketsandMarkets. "Allergy and Asthma Therapeutics Market." 2022.